Pfenex Inc.

Eli Lilly and Company

Dow Global Technolgoies LLC

Dow Agrosciences LLC

Charles H. Squires

Diane M. Retallack

David C. Watkins

Frank H. Gaertner

Robert Shutter

Stacey Lynn Lee

Diane M Retallack

Frank H Gaertner

David K Watkins

Charles H Squires

Russell J Coleman

Charles D Hershberger

Petra Verdino

Thomas Martin Ramseier

Jane C Schneider

Sol M Resnick

Lawrence C Chew

Mark Andrew Wortinger

Henry W Talbot

Xiaojun Wang

Paul Francis Cain

Melinda Ann Lacerte

Sol Resnick

David C Watkins

Thomas M Ramseier

Russell John Coleman

Charles Douglas Hershberger

Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity. Pharmaceutical compositions also are disclosed that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the RLN analogs also are disclosed, especially for treating cardiovascular, pulmonary and/or renal conditions, diseases or disorders.

Relaxin analogs and methods of using the same

The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.

GITR antagonists and methods of using the same

The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in aorganism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such asin comparable circumstances. Processes for improved production of isolated mammalian, particularly human, proteins are provided.

[object Object]

The invention is a process for improved production of a recombinant mammalian protein by expression in a Pseudomonad, particularly in aorganism. The process improves production of mammalian proteins, particularly human or human-derived proteins, over known expression systems such asin comparable circumstances Processes for improved production of isolated mammalian, particularly human, proteins are provided.

Provided herein are improved copy number plasmids, particularly those plasmids capable of replication in a bacterial cell. The improved copy number plasmid contain a deletion, insertion, or substitution in the replication control region, particularly a-specific replication control region, that results in an increase in plasmid copy number in comparison to a control plasmid. Also provided are host cells containing the improved copy number plasmids, as well as methods of using the improved copy number plasmids for the recombinant production of a protein of interest. Further provided are methods for generating plasmids with improved copy number. The methods disclosed herein involve the reiterative selection of improved copy number plasmids by the growth and selection of plasmids capable of growth under increasing selective pressure, wherein the selective pressure is applied utilizing a selection agent to which the control plasmid confers resistance.

High copy number self-replicating plasmids in pseudomonas

Compositions and methods for improving expression and/or secretion of a polypeptide of interest in a host cell are provided. Compositions including a coding sequence for a bacterial secretion signal peptide are provided. The compositions of the invention are useful for increasing accumulation of properly processed proteins in the periplasmic space of a host cell, or for increasing secretion of properly processed proteins. In particular, isolated secretion signal peptide-encoding nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the nucleic acid molecules are encompassed. The present invention provides for isolated nucleic acid molecules including nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24, and the nucleotide sequences set forth in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, as well as variants and fragments thereof.

Bacterial leader sequences for increased expression

Compositions and methods for improving expression and/or secretion of protein or polypeptide of interest in a host cell are provided. Compositions comprising a coding sequence for a bacterial secretion signal peptide are provided. The coding sequences can be used in vector constructs or expression systems for transformation and expression of a protein or polypeptide of interest in a host cell. The compositions of the invention are useful for increasing accumulation of properly processed proteins in the periplasmic space of a host cell, or for increasing secretion of properly processed proteins from the host cell. In particular, isolated secretion signal peptide-encoding nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the nucleic acid molecules are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24, and the nucleotide sequences set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, as well as variants and fragments thereof.

The present invention provides active cytokine and/or chemokine compositions, as well as inexpensive means for the production, amended-cell encasement of active cytokine and/or chemokine compositions, processing, and delivery of active cytokine and/or chemokine compositions. The subject invention also provides methods of treatment and methods of accelerating an immune response comprising the administration of amended recombinant cell (ARC) containing cytokine and/or chemokine compositions to animals or humans.

Amended recombinant cells for the production and delivery of gamma interferon as an antiviral agent, adjuvant and vaccine accelerant

Growing community of inventors

San Diego, CA, United States of America

Stacey Lynn Lee